US20120220559A1 - Controlled Release and Taste Masking Oral Pharmaceutical Composition - Google Patents
Controlled Release and Taste Masking Oral Pharmaceutical Composition Download PDFInfo
- Publication number
- US20120220559A1 US20120220559A1 US13/462,430 US201213462430A US2012220559A1 US 20120220559 A1 US20120220559 A1 US 20120220559A1 US 201213462430 A US201213462430 A US 201213462430A US 2012220559 A1 US2012220559 A1 US 2012220559A1
- Authority
- US
- United States
- Prior art keywords
- matrix
- active ingredient
- inert
- hydrophilic
- lipophilic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Definitions
- the present invention relates to controlled release and taste masking compositions containing budesonide as active ingredient incorporated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally incorporated or dispersed in hydrophilic matrices.
- a three-component matrix structure i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally incorporated or dispersed in hydrophilic matrices.
- the use of a plurality of systems mechanism for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract, and it also allows the oral administration of active principles having unfavourable taste characteristics or irritating action on the mucosae of the administration site, particularly in the buccal or gastric area.
- compositions of the invention are suitable to the oral administration or the efficaciously deliver the active ingredient acting topically at some areas of the gastrointestinal tract.
- inert matrices in which the main component of the matrix structure opposes some resistance to the penetration of the solvent due to the poor affinity towards aqueous fluids; such property being known as lipophilia.
- hydrophilic matrices in which the main component of the matrix structure opposes high resistance to the progress of the solvent, in that the presence of strongly hydrophilic groups in its chains, mainly branched, remarkably increases viscosity inside the hydrated layer.
- bioerodible matrices which are capable of being degraded by the anzimes of some biological compartment.
- Inert matrices for example, generally entail non-linear, but exponential, release of the active ingredient.
- Hydrophilic matrices have a linear behaviour until a certain fraction of active ingredient has been released, then significantly deviate from linear release.
- Bioerodible matrices are ideal to carry out the so-called “sire-release”, but they involve the problem of finding the suitable enzyme or reactive to degradation. Furthermore, they frequently release in situ metabolites that are not wholly toxicologically inert.
- the inert carrier is kneaded with the solution containing the inert polymer and the active ingredient, then the organic solvent used for the their dissolution is evaporated off to obtain a solid residue.
- the resulting structure is a “reservoir”, i.e. is not macroscopically homogeneous along all the symmetry axis of the final form.
- the same “reservoir” structure is also described in Chem. Pharm. Bull. 46 (3), 531-533, (1998) which improves the application through an annealing technique of the inert polymer layer which is deposited on the surface of the pellets.
- WO 93/00889 discloses a process for the preparation of pellets in hydrophilic matrix which comprises: —dissolution of the active ingredient with gastro resistant hydrophilic polymers in organic solvents; —diying of said suspension; —subsequent kneading and formulation of the pellets in a hydrophilic or lipophilic matrix without distinction of effectiveness between the two types of application.
- EP 0 453 001 discloses a multiparticulate with “reservoir” structure inserted in a hydrophilic matrix.
- the basic multiparticulate utilizes two coating membranes to decrease the release rate of the active ingredient, a pH-dependent membrane with the purpose of gastric protection and a pH-independent methacrylic membrane with the purpose of slowing down the penetration of the aqueous fluid.
- WO 95/16451 discloses a composition only formed by a hydrophilic matrix coated with a gastro-resistant film for controlling the dissolution rate of the active ingredient.
- compositions of the invention are characterized by the absence of a first phase in which the medicament superficially present on the matrix is quickly solubilized, and by the fact the amphiphilic layer compensate the lack of affinity of the aqueous solvent with the lipophilic compounds forming the inner inert matrix.
- the invention provides controlled release and taste masking oral pharmaceutical compositions containing as active ingredient budesonide comprising:
- a particular aspect of the invention consists of controlled release oral compositions containing as active ingredient budesonide comprising:
- a further aspect of the invention provides taste masking oral pharmaceutical compositions budesonide containing comprising:
- an inert or lipophilic matrix consisting of C6-C20 alcohols or C8-C20 fatty acids or esters of fatty acids with glycerol or sorbitol or other polyalcohols with carbon atom chain not higher than six: an amphiphilic matrix consisting of polar lipids of type I or II or glycols partially etherified with C1-C4 alkyl chains; an outer hydrophilic matrix containing the above matrices, mainly formed by saccharide, dextrin, polyalcohol or cellulose compounds or by hydrogels or their mixtures; optional excipients to give stability to the pharmaceutical formulation.
- compositions of the invention can be prepared by a method comprising the following steps:
- the active ingredient represented by budesonide
- a matrix or coating consisting of compounds having amphiphilic properties, which will be further specified below.
- the active ingredient can be mixed with the amphiphilic compounds without the aid of solvents or with small amounts of water-alcoholic solvents.
- the matrix obtained as specified under a) is incorporated in a low melting lipophilic excipient or mixture of excipients, if necessary while heating to soften and/or melt the excipient itself, which thereby incorporates the active ingredient by simple dispersion forming an inert matrix which can be reduced in size to obtain inert matrix granules containing the active ingredient particles.
- the inert matrix granules are subsequently mixed together with one or more hydrophilic water-swellable excipients.
- the mixture is then subjected to compression or tabletting. This way, when the tablet is contacted with biological fluids, a high viscosity swollen layer is formed, which coordinates the solvent molecules and acts as a barrier to penetration of the aqueous fluid itself inside the new structure. Said barrier antagonizes the starting “burst effect” caused by the dissolution of the medicament inglobated inside the inert matrix, which is in its turn inside the hydrophilic matrix.
- amphiphilic compounds which can be used according to the invention comprise polar lipids of type I or II (lecithin, phosphatidylcholine, phosphatidylethanolainine), ceramides, glycol alkyl ethers such as diethylene glycol monomethyl ether (Transcutol ⁇ R>)
- the lipophilic matrix consists of substances selected from unsaturated or hydrogenated alcohols or fatty acids, salts, esters or amides thereof, fatty acids mono-, di- or triglycerids, the polyethoxylated derivatives thereof, waxes, ceramides, cholesterol derivatives or mixtures thereof having melting point within the range of 40 to 90° C., preferably from 60 to 70 C.
- a fatty acid calcium salt may be incorporated in the lipophilic matrix which is subsequently dispersed in a hydrophilic matrix prepared with alginic acid, thus remarkably increasing the hydrophilic matrix viscosity following penetration of the solvent front until contact with the lipophilic matrix granules dispersed inside.
- amphiphilic matrix with high content in active ingredient is first prepared by dispersing the active ingredient in a mixture of amphiphilic compounds, such as lecithin, other type II polar lipids, surfactants, or in diethylene glycol monoethyl ether; the resulting amphiphilic matrix is then mixed or lcneaded, usually while hot, with lipophilic compounds suitable to form an inert matrix, such as saturated or unsaturated fatty acids, such as palmitic, stearic, myristic, (auric, laurylic, or oleic acids or mixtures thereof with other fatty acids with shorter chain, or salts or alcohols or derivatives of the cited fatty acids, such as mono-, di-, or triglycerids or esters with polyethylene glycols, alone or in combination with waxes, ceramides, cholesterol derivatives or other apolar lipids in various ratios so that the melting or soft
- the order of formation of the inert and amphiphilic matrices can be reversed, incorporating the inert matrix inside the amphiphilic compounds.
- the resulting inert lipophilic matrix is reduced into granules by an extrusion and/or granulation process, or any other known processes which retain the homogeneous dispersion and matrix structure of the starting mixture.
- the hydrophilic matrix consists of excipients known as hydrogels, i.e. substances which when passing from the dry state to the hydrated one, undergo the so-called “molecular relaxation”, namely a remarkable increase in mass and weight following the coordination of a large number of water molecules by the polar groups present in the polymeric chains of the excipients themselves.
- hydrogels which can be used according to the invention are compounds selected from acrylic or methacrylic acid polymers or copolymers, alkylvinyl polymers, hydroxyalkyl celluloses, carboxyalkyl celluloses, polysaccharides, dextrins, pectins, starches and derivatives, natural or synthetic gums, alginic acid.
- polyalcohols such as xylitol, maltitol and mannitol as hydrophilic compounds can also be advantageous.
- the lipophilic matrix granules containing the active ingredient are mixed with the hydrophilic compounds cited above in a weight ratio typically ranging from 100:0.5 to 100:50 (lipophilic matrix: hydrophilic matrix).
- Part of the active ingredient can optionally be mixed with hydrophilic substances to provide compositions in which the active ingredient is dispersed both in the lipophilic and the hydrophilic matrix, said compositions being preferably in the form of tablets, capsules and/or minitablets.
- the compression of the mixture of lipophilic and/or amphiphilic matrix, hydrogel-forming compound and, optionally, active ingredient not inglobated in the lipophilic matrix yields a macroscopically homogeneous structure in all its volume, namely a matrix containing a dispersion of the lipophilic granules in a hydrophilic matrix.
- a similar result can also be obtained by coating the lipophilic matrix granules with a hydrophilic polymer coating.
- the tablets obtainable according to the invention are subjected to known coating processes with a gastro-resistant film, consisting of, for example, acrylic and methacrylic acids polymers (Eudragit (R)) or copolymer or cellulose derivatives, such as cellulose acetophthalate.
- the composition of the invention can further contain conventional excipients, for example bioadhesive excipients such as chitosans, polyacrylamides, natural or synthetic gums, acrylic acid polymers.
- compositions of the invention are preferably in the form of tablets, capsules or minitablets.
- contact with water or aqueous fluids causes the immediate penetration of water inside the more superficial layer of the matrix which, thanks to the presence of the aqueous solvent, swells due to the distension of the polymeric chains of the hydrogels, giving rise to a high viscosity hydrated front which prevents the further penetration of the solvent itself linearly slowing down the dissolution process to a well determined point which can be located at about half the thickness, until the further penetration of water would cause the disintegration of the hydrophilic layer and therefore the release of the content which, consisting of inert matrix granules, however induces the diffusion mechanism typical of these structures and therefore further slows down the dissolution profile of the active ingredient.
- amphiphilic matrix inside the lipophilic matrix inert allows to prevent any unevenness of the release profile of the active ingredient.
- the surfactants present in the amphiphilic portion promote wettability of the porous canaliculuses which cross the inert matrix preventing or reducing resistance to penetration of the solvent inside the inert matrix.
- the components of the hydrophilic matrix are carefully selected to minimize the active substance release time through penetration accelerated by the canalization induced by the hydrophilic compound.
- dissolution Test Method To test the effective ability of the formulations of the invention to modify the release rate and extent of the active ingredient from the dosage form suitable for the drug administration, before any pharmacokinetic study on patients or volunteers, the dissolution test is taken as monitoring and discriminating tool. Dissolution Test Method.
- Tablets according to the present invention undergo to dissolution test to verify the formulation capacity in modulating and controlling the rate by which the active ingredient is leaked by the device or dosage form in the environmental medium, generally a buffered solution simulating gastric or intestinal juices.
- pH 1, 6.4 and 7.2 are the pH condition generally used in this test applications
- the tablets according to the present invention when designed to be used to treat inflammatory bowel disease, in principle have to show a good resistance, thanks to the polymeric film resistant to the low pH conditions (intended as ⁇ 5 to simulate the gastric environment) applied to cover the tablet surface, resistance which last at least for two hours; to target the large intestinal sectors, also the pH condition of 6.4 shown unsuitability to determine a drug leakage from the administration device for a short exposition time and only mediums at pH 7.2 have been able to determine an active ingredient dissolution at a progressive and quite constant rate during a timeframe from 6 to 12 hours; the dissolution percentage obtained with this tablet formulation were below 15% at first hour sampling, below 25% at second hour sampling, then values were in the range 25% to 55% at fourth hour and a dissolution greater than 80% was achieved at 8 th hour sampling.
- 2.7 kg of budesonide, 3.0 kg of lecithin (amphiphilic matrix forming material) and 3.0 kg of stearic acid (lipophilic matrix forming material) are mixing after sieving till an homogeneous mixture is obtained; then add 39.0 kg of inert, functional excipients and 9.0 kg of low viscosity hydroxypropylcellulose (binder) and mix for 10 minutes before adding purified water and kneading to a suitable consistence. Then pass the granulate through a rotating granulator equipped with the suitable screen and transfer the granulate to the fluid bed drier to lower the residual moisture content under 3%.
- the granulate is added of 9.0 kg of hydroxypropylcellulose (hydrophilic matrix forming material) and the suitable amount of functional excipients (in particular, microcrystalline cellulose, lactose and silicon dioxide) and, after 15 minutes of mixing, magnesium stearate in a suitable quantity to act as lubricant is added.
- hydroxypropylcellulose hydrophilic matrix forming material
- functional excipients in particular, microcrystalline cellulose, lactose and silicon dioxide
- the core are then subjected to be coated with a suspension obtained introducing into a stainless steel container 5.8 kg of EudragitTM (methacrylate copolymers), 0.6 kg of triethylcitrate and 3.0 kg of dyes and talc, using alcohol as solvent.
- the mean dissolution percentage (as average of six or more tablets) obtained with this tablet formulation were around 10-20% at second hour sampling, in the range 25% to 65% at fourth hour and a dissolution greater than 80% was achieved at 8 th hour sampling.
- coated tablets individually weighing about 220 mg are obtained.
- Budesonide (3.0 kg) is mixed with soybean Lecithin (5.0 kg) till an homogeneous mixture is obtained. Then carnauba wax (2.0 kg) and stearic acid (2.0 kg) sieved through a fine screen are added. After mixing, the powders are added with other functional excipients and kneaded with a binder solution obtained by dissolving medium viscosity polyvinylpirrolidone in water. After drying in a fluid bed and milling throughout a suitable screen, hydroxypropylmethylcellulose (35.0 kg) and other excipients, including magnesium stearate as lubricant, in a suitable quantity are added and the mixture is blended till an homogeneous powder dispersion is obtained.
- the powder mixture is subjected to compression in a rotating tabletting machine and the tablets so obtained are coated in a pan coat with a gastroresistant composition containing EudragitTM, plasticizers, dyes and pigments.
- coated tablets individually weighing around 105 mg are obtained.
- a suitable mixer is loaded with the matrix granules prepared as above and the following amounts of hydrophilic excipients: 1500 g of hydroxypropyl methylcellulose and 500 g of PolicarbophilTM are added. The components are mixed until homogeneous dispersion of the matrices, then added with 2450 g of microcrystalline cellulose, 400 g of lactose, 100 g of colloidal silica and 50 g of magnesium stearate. After further 5 minute mixing, the mix is tabletted to unitary weight of 250 mg/tablet.
- Tablets are then subjected to coating using a suspension n containing polyacrylate and poly methacrilate copolymers in addition to other dyes, plasticizers and colouring agents in solvent (ethylic alcohol).
- solvent ethylic alcohol
- the inert matrix granules are loaded into a mixer in which 30 g of carbopol 971 P and 65 g of hydroxypropyl methylcellulose “are sequentially added.” After a first mixing step for homogeneously dispersing the powders, 60 g of microcrystalline cellulose and 5 g of magnesium stearate are added. After mixing, the final mixture is tabletted to unitary weight of 760 mg/tablet. The resulting tablets are film-coated with cellulose acetophthalate or polymethacrylates and a plasticizer to provide gastric resistance and prevent the early release of product in the stomach.
- the resulting tablets when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 60 minutes no more than 30%, after 180 minutes no more than 60%, after 5 hours no more than 80%.
- a suitable mixer is loaded with the matrix granules prepared as above and the following amounts of hydrophilic excipients: 1500 g of hydroxypropyl methylcellulose and 500 g of policarbophil.
- the components are mixed until homogeneous dispersion of the matrices, then added with 2450 g of microcrystalline cellulose, 400 g of lactose, 100 g of colloidal silica and 50 g of magnesium stearate. After further 5 minute mixing, the mix is tabletted to unitary weight of 250 mg/tablet.
- metformin 850 g of metformin are dispersed in a granulator/kneader with 35 g of diethylene glycol monoethyl ether previously melted with 100 g of stearic acid and 55 g of carnauba wax.
- the system is heated to carry out the granulation of the active ingredient in the inert matrix.
- the resulting 1040 g of formulation are added with 110 g of hydroxypropyl methylcellulose and 20 g of magnesium stearate.
- the final mixture is tabletted to unitary weight of 1170 mg/tablet equivalent to 850 mg of active ingredient.
- the resulting tablets when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 60 minutes no more than 35%, after 180 minutes no more than 60%, after 5 hours no more than 80%.
- 120 g of octylonium bromide are dispersed in a granulator/kneader with 30 g of stearic acid and 15 g of beeswax in which 10 g of diethylene glycol monoethylene had previously been melted.
- the system is heated to carry out the granulation of the active ingredient in the inert matrix.
- the resulting 10 g of formulation are added with 5 g of hydroxypropyl methylcellulose and 5 g of policarbophyl, 2 g of magnesium stearate and 3 g of microcrystalline cellulose.
- the final mixture is tabletted to unitary weight of 200 mg/tablet equivalent to 120 mg of active ingredient.
- the resulting tablets when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 60 minutes no more than 25%; after 180 minutes no more than 50%; after 5 hours no more than 70%.
- the system is heated to carry out the granulation of the active ingredient in the inert matrix.
- the resulting 340 g (170 g) of formulation are added with 20 g (10 g) of hydroxypropyl methylcellulose, 10 g (5 g) of xantangum, 16 g (8 g) of microcrystalline cellulose, 4 g (2 g) of magnesium stearate.
- the final mixture is tabletted to unitary weight of 400 (200) mg/tablet equivalent to 50 (25) mg of carbidopa and 200 ( ⁇ 100) mg di levodopa.
- Nimesulide 4 g are solubilised in 50 g of diethylene glycol monoethyl ether, then 100 g of microcrystalline cellulose are added to obtain a homogeneous mixture.
- the resulting mixture is added in a granulator/kneader with 196 g of Nimesulide, 50 g of stearic acid and 25 g of carnauba wax.
- the system is heated to carry out the granulation of the active ingredient in the inert and amphiphilic matrix system.
- the final mixture is tabletted to unitary weight of 500 mg/tablet equivalent to 200 mg of active ingredient.
- the resulting tablets when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 1 hour no more than 25%, after 2 hours no more than 40%, after 4 hours no more than 60%, after 8 hours no more than 90%.
- propionyl carnitine 500 g are dispersed in a granulator/kneader with 90 g of stearic acid and 40 g of carnauba wax, in which 20 g of diethylene glycol monoethyl ether had previously been melted.
- the system is heated to carry out the granulation of the active ingredient in the inert/amphiphilic matrix.
- the resulting 650 g of formulation are added with 60 g of hydroxypropyl methylcellulose and 10 g of magnesium stearate.
- the final mixture is tabletted to unitary weight of 720 mg/tablet equivalent to 500 mg of active ingredient.
- the resulting tablets when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 60 minutes no more than 40%, after 180 minutes no more than 60%, after 4 hours no more than 80%, after 8 hours no more than 90%.
- Nimesulide is placed in a high rate granulator, pre-heated to about 70°, together with 200 g of cetyl alcohol and 25 g of glycerol palmitostearate the mixture is kneaded for about 15 minutes and stirred while decreasing temperature to about 30° C.
- the resulting inert matrix is added, keeping stirring and kneading during cooling, with 50 g of soy lecithin and 50 g of ethylene glycol monoethyl ether.
- the granulate is extruded through a metallic screen of suitable size and mixed with 50 g of hydroxypropyl methylcellulose, 1320 kg of maltodextrins, 2 kg of lactose-cellulose mixture, 50 g of colloidal silica, 40 g of aspartame, 150 g of citric acid, 75 g of flavour and 65 g of magnesium stearate.
- the final mixture is tabletted to unitary weight of about 500 mg, having hardness suitable for being dissolved in the mouth and a pleasant taste.
- chewable tablets are prepared replacing dextrin with mannitol and the lactose-cellulose mixture with xylitol.
- the resulting tablets have pleasant taste and give upon chewing a sensation of freshness enhancing the flavour.
- active ingredient ibuprofen mg 100 lipophilic/inert matrix component: mg 15 cetyl alcohol amphiphilic matrix component: mg 8 soy lecithin hydrophilic matrix components: mannitol mg 167 maltodextrins mg 150 methylhydroxypropylcellulose mg 30 adjuvants: aspartame mg 15 flavour mg 5 colloidal silica mg 5 magnesium stearate mg 5
- 500 mg unitary weight tablets are obtained, which undergo progressive erosion upon buccal administration, and effectively mask the bitter, irritating taste of the active ingredient.
- active ingredient diclofenac sodium mg 25 lipophilic/inert matrix component: mg 5 cetyl alcohol glycerol palmitostearate mg 5 amphiphilic matrix component: mg 7 soy lecithin hydrophilic matrix components: xylitol mg 168 maltodextrins mg 150 hydroxypropylmethylcellulose mg 20 adjuvants: aspartame mg 5 flavour mg 5 colloidal silica mg 5 magnesium stearate mg 5
- 400 mg unitary weight tablets are obtained, which undergo progressive erosion upon buccal administration, and effectively mask the irritating taste of the active ingredient.
- active ingredient chlorhexidine mg
- 2.5 lipophilic/inert matrix component mg 0.5 cetyl alcohol glycerol palmitostearate mg
- amphiphilic matrix component mg 0.3 diethylene glycol monoethyl ether hydrophilic matrix components: xylitol mg 38 maltodextrins mg 96 hydroxypropyl methylcellulose mg 10 adjuvants: aspartame mg 3 flavour mg 5 colloidal silica mg 2 magnesium stearate mg 2
- 150 mg unitary weight tablets are obtained, which undergo progressive erosion upon buccal administration, and effectively mask the irritating taste of the active ingredient.
- Nimesulide is placed in a high rate granulator, pre-heated to about 70°, together with g 125 of cetyl alcohol: the mixture is kneaded for about 15 minutes and stirred while decreasing temperature to about 30° C., then added with g 30 of lecithin.
- the resulting matrix is then extruded through a metallic screen of suitable size and mixed with 2.415 kg of lactose, 1.0 kg of maltodextrins, 50 g of hydroxypropyl methylcellulose, 50 g of colloidal silica, 40 g of aspartame, 150 g of citric acid, 75 g of flavour and 65 g of magnesium stearate.
- the final mixture is tabletted to about 500 mg tablets, having hardness suitable for being dissolved in the mouth and pleasant taste.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
Description
- This application is a continuation of application Ser. No. 13/249,839 filed on Sep. 30, 2011; which is a continuation of application Ser. No. 12/210,969 filed on Sep. 15, 2008, now U.S. Pat. No. 8,029,823; which is a continuation-in-part of application Ser. No. 10/009,532 filed on Dec. 12, 2001, now U.S. Pat. No. 7,431,943; which is the 35 U.S.C. 371 national stage of International application PCT/EP00/05356 filed on Jun. 9, 2000; which claimed priority to Italian applications MI2000A000422 and MI199A001317 filed Mar. 3, 2000 and Jun. 14, 1999, respectively. The entire contents of each of the above-identified applications are hereby incorporated by reference.
- The present invention relates to controlled release and taste masking compositions containing budesonide as active ingredient incorporated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally incorporated or dispersed in hydrophilic matrices. The use of a plurality of systems mechanism for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract, and it also allows the oral administration of active principles having unfavourable taste characteristics or irritating action on the mucosae of the administration site, particularly in the buccal or gastric area.
- The compositions of the invention are suitable to the oral administration or the efficaciously deliver the active ingredient acting topically at some areas of the gastrointestinal tract.
- The preparation of a sustained, controlled, delayed, extended or anyhow modified release form can be carried out according to different techniques:
- 1. The use of inert matrices, in which the main component of the matrix structure opposes some resistance to the penetration of the solvent due to the poor affinity towards aqueous fluids; such property being known as lipophilia.
2. The use of hydrophilic matrices, in which the main component of the matrix structure opposes high resistance to the progress of the solvent, in that the presence of strongly hydrophilic groups in its chains, mainly branched, remarkably increases viscosity inside the hydrated layer.
3. The use of bioerodible matrices, which are capable of being degraded by the anzimes of some biological compartment. - All the procedures listed above suffer, however, from drawbacks and imperfections.
- Inert matrices, for example, generally entail non-linear, but exponential, release of the active ingredient.
- Hydrophilic matrices: have a linear behaviour until a certain fraction of active ingredient has been released, then significantly deviate from linear release.
- Bioerodible matrices are ideal to carry out the so-called “sire-release”, but they involve the problem of finding the suitable enzyme or reactive to degradation. Furthermore, they frequently release in situ metabolites that are not wholly toxicologically inert.
- A number of formulations based on inert lipophilic matrices have been described: Drug Dev. Ind. Pharm. 13 (6), 1001-1022, (1987) discloses a process making use of varying amounts of colloidal silica as a porization element for a lipophilic inert matrix in which the active ingredient is incorporated
- The same notion of canalization of an inert matrix is described in U.S. Pat. No. 4,608,248 in which a small amount of a hydrophilic polymer is mixed with the substances forming an inert matrix, in a non sequential compenetration of different matrix materials. EP 375,063 discloses a technique for the preparation of multiparticulate granules for the controlled-release of the active ingredient which comprises co-dissolution of polymers or suitable substances to form a inert matrix with the active ingredient and the subsequent deposition of said solution on an inert carrier which acts as the core of the device. Alternatively, the inert carrier is kneaded with the solution containing the inert polymer and the active ingredient, then the organic solvent used for the their dissolution is evaporated off to obtain a solid residue. The resulting structure is a “reservoir”, i.e. is not macroscopically homogeneous along all the symmetry axis of the final form. The same “reservoir” structure is also described in Chem. Pharm. Bull. 46 (3), 531-533, (1998) which improves the application through an annealing technique of the inert polymer layer which is deposited on the surface of the pellets.
- To the “reservoir” structure also belong the products obtained according to the technique described in WO 93/00889 which discloses a process for the preparation of pellets in hydrophilic matrix which comprises: —dissolution of the active ingredient with gastro resistant hydrophilic polymers in organic solvents; —diying of said suspension; —subsequent kneading and formulation of the pellets in a hydrophilic or lipophilic matrix without distinction of effectiveness between the two types of application. EP 0 453 001 discloses a multiparticulate with “reservoir” structure inserted in a hydrophilic matrix. The basic multiparticulate utilizes two coating membranes to decrease the release rate of the active ingredient, a pH-dependent membrane with the purpose of gastric protection and a pH-independent methacrylic membrane with the purpose of slowing down the penetration of the aqueous fluid. WO 95/16451 discloses a composition only formed by a hydrophilic matrix coated with a gastro-resistant film for controlling the dissolution rate of the active ingredient. When preparing sustained-, controlled-release dosage forms of a medicament topically active in the gastrointestinal tract, it is important to ensure a controlled release from the first phases following administration, i.e. when the inert matrices have the maximum release rate inside the logarithmic phase, namely the higher deviation from linear release. Said object has been attained according to the present invention, through the combination of an amphiphilic matrix inside an inert matrix, the latter formulated with a lipophilic polymer in a superficial hydrophilic matrix. The compositions of the invention are characterized by the absence of a first phase in which the medicament superficially present on the matrix is quickly solubilized, and by the fact the amphiphilic layer compensate the lack of affinity of the aqueous solvent with the lipophilic compounds forming the inner inert matrix.
- The invention provides controlled release and taste masking oral pharmaceutical compositions containing as active ingredient budesonide comprising:
- a) a matrix consisting of lipophilic compounds with melting point lower than 90[deg.] C. and optionally by amphiphilic compounds in which the active ingredient is at least partially incorporated;
b) an amphiphilic matrix;
c) an outer hydrophilic matrix in which the lipophilic matrix and the amphiphilic matrix are dispersed;
d) optionally other excipients. - A particular aspect of the invention consists of controlled release oral compositions containing as active ingredient budesonide comprising:
- a) a matrix consisting of amphiphilic compounds and lipophilic compounds with melting point below 90° C. in which the active ingredient is at least partially incorporated;
b) an outer hydrophilic matrix in which the lipophilic/amphiphilic matrix is dispersed, preferably by mixing;
c) optionally other excipients. - A further aspect of the invention provides taste masking oral pharmaceutical compositions budesonide containing comprising:
- an inert or lipophilic matrix consisting of C6-C20 alcohols or C8-C20 fatty acids or esters of fatty acids with glycerol or sorbitol or other polyalcohols with carbon atom chain not higher than six:
an amphiphilic matrix consisting of polar lipids of type I or II or glycols partially etherified with C1-C4 alkyl chains;
an outer hydrophilic matrix containing the above matrices, mainly formed by saccharide, dextrin, polyalcohol or cellulose compounds or by hydrogels or their mixtures;
optional excipients to give stability to the pharmaceutical formulation. - The compositions of the invention can be prepared by a method comprising the following steps:
- a) the active ingredient, represented by budesonide, is first inglobated by simple kneading or mixing in a matrix or coating consisting of compounds having amphiphilic properties, which will be further specified below. The active ingredient can be mixed with the amphiphilic compounds without the aid of solvents or with small amounts of water-alcoholic solvents.
b) the matrix obtained as specified under a) is incorporated in a low melting lipophilic excipient or mixture of excipients, if necessary while heating to soften and/or melt the excipient itself, which thereby incorporates the active ingredient by simple dispersion forming an inert matrix which can be reduced in size to obtain inert matrix granules containing the active ingredient particles.
c) the inert matrix granules are subsequently mixed together with one or more hydrophilic water-swellable excipients. The mixture is then subjected to compression or tabletting. This way, when the tablet is contacted with biological fluids, a high viscosity swollen layer is formed, which coordinates the solvent molecules and acts as a barrier to penetration of the aqueous fluid itself inside the new structure. Said barrier antagonizes the starting “burst effect” caused by the dissolution of the medicament inglobated inside the inert matrix, which is in its turn inside the hydrophilic matrix. The amphiphilic compounds which can be used according to the invention comprise polar lipids of type I or II (lecithin, phosphatidylcholine, phosphatidylethanolainine), ceramides, glycol alkyl ethers such as diethylene glycol monomethyl ether (Transcutol<R>) The lipophilic matrix consists of substances selected from unsaturated or hydrogenated alcohols or fatty acids, salts, esters or amides thereof, fatty acids mono-, di- or triglycerids, the polyethoxylated derivatives thereof, waxes, ceramides, cholesterol derivatives or mixtures thereof having melting point within the range of 40 to 90° C., preferably from 60 to 70 C. If desired, a fatty acid calcium salt may be incorporated in the lipophilic matrix which is subsequently dispersed in a hydrophilic matrix prepared with alginic acid, thus remarkably increasing the hydrophilic matrix viscosity following penetration of the solvent front until contact with the lipophilic matrix granules dispersed inside. An amphiphilic matrix with high content in active ingredient, typically from 5 to 95% w/w, in particular from 20 to 70%, is first prepared by dispersing the active ingredient in a mixture of amphiphilic compounds, such as lecithin, other type II polar lipids, surfactants, or in diethylene glycol monoethyl ether; the resulting amphiphilic matrix is then mixed or lcneaded, usually while hot, with lipophilic compounds suitable to form an inert matrix, such as saturated or unsaturated fatty acids, such as palmitic, stearic, myristic, (auric, laurylic, or oleic acids or mixtures thereof with other fatty acids with shorter chain, or salts or alcohols or derivatives of the cited fatty acids, such as mono-, di-, or triglycerids or esters with polyethylene glycols, alone or in combination with waxes, ceramides, cholesterol derivatives or other apolar lipids in various ratios so that the melting or softening points of the lipophilic compounds mixtures is within the range of 40 to 90 C, preferably from 60 to 70 C. Alternatively, the order of formation of the inert and amphiphilic matrices can be reversed, incorporating the inert matrix inside the amphiphilic compounds. The resulting inert lipophilic matrix is reduced into granules by an extrusion and/or granulation process, or any other known processes which retain the homogeneous dispersion and matrix structure of the starting mixture. The hydrophilic matrix consists of excipients known as hydrogels, i.e. substances which when passing from the dry state to the hydrated one, undergo the so-called “molecular relaxation”, namely a remarkable increase in mass and weight following the coordination of a large number of water molecules by the polar groups present in the polymeric chains of the excipients themselves. Examples of hydrogels which can be used according to the invention are compounds selected from acrylic or methacrylic acid polymers or copolymers, alkylvinyl polymers, hydroxyalkyl celluloses, carboxyalkyl celluloses, polysaccharides, dextrins, pectins, starches and derivatives, natural or synthetic gums, alginic acid. In case of taste-masking formulations, the use of polyalcohols such as xylitol, maltitol and mannitol as hydrophilic compounds can also be advantageous. The lipophilic matrix granules containing the active ingredient are mixed with the hydrophilic compounds cited above in a weight ratio typically ranging from 100:0.5 to 100:50 (lipophilic matrix: hydrophilic matrix). Part of the active ingredient can optionally be mixed with hydrophilic substances to provide compositions in which the active ingredient is dispersed both in the lipophilic and the hydrophilic matrix, said compositions being preferably in the form of tablets, capsules and/or minitablets. The compression of the mixture of lipophilic and/or amphiphilic matrix, hydrogel-forming compound and, optionally, active ingredient not inglobated in the lipophilic matrix, yields a macroscopically homogeneous structure in all its volume, namely a matrix containing a dispersion of the lipophilic granules in a hydrophilic matrix. A similar result can also be obtained by coating the lipophilic matrix granules with a hydrophilic polymer coating. The tablets obtainable according to the invention are subjected to known coating processes with a gastro-resistant film, consisting of, for example, acrylic and methacrylic acids polymers (Eudragit (R)) or copolymer or cellulose derivatives, such as cellulose acetophthalate. The composition of the invention can further contain conventional excipients, for example bioadhesive excipients such as chitosans, polyacrylamides, natural or synthetic gums, acrylic acid polymers. - The compositions of the invention are preferably in the form of tablets, capsules or minitablets. In terms of dissolution characteristics, contact with water or aqueous fluids causes the immediate penetration of water inside the more superficial layer of the matrix which, thanks to the presence of the aqueous solvent, swells due to the distension of the polymeric chains of the hydrogels, giving rise to a high viscosity hydrated front which prevents the further penetration of the solvent itself linearly slowing down the dissolution process to a well determined point which can be located at about half the thickness, until the further penetration of water would cause the disintegration of the hydrophilic layer and therefore the release of the content which, consisting of inert matrix granules, however induces the diffusion mechanism typical of these structures and therefore further slows down the dissolution profile of the active ingredient. The presence of the amphiphilic matrix inside the lipophilic matrix inert allows to prevent any unevenness of the release profile of the active ingredient. The surfactants present in the amphiphilic portion promote wettability of the porous canaliculuses which cross the inert matrix preventing or reducing resistance to penetration of the solvent inside the inert matrix. To obtain taste masking tablets, the components of the hydrophilic matrix are carefully selected to minimize the active substance release time through penetration accelerated by the canalization induced by the hydrophilic compound.
- To test the effective ability of the formulations of the invention to modify the release rate and extent of the active ingredient from the dosage form suitable for the drug administration, before any pharmacokinetic study on patients or volunteers, the dissolution test is taken as monitoring and discriminating tool. Dissolution Test Method.
- Tablets according to the present invention undergo to dissolution test to verify the formulation capacity in modulating and controlling the rate by which the active ingredient is leaked by the device or dosage form in the environmental medium, generally a buffered solution simulating gastric or intestinal juices.
- The dissolution test is performed by introducing individual tablets in a glace vessel containing from 500 to 1000 ml of a buffered solution set to different pH conditions (pH 1, 6.4 and 7.2 are the pH condition generally used in this test applications), so that the whole digestive tract pH conditions, from stomach to large intestine, should be reproduced. To simulate the human body conditions, the test is carried out at a temperature of 37° C.+-<=2° C. and at predetermined time periods samples of the dissolution medium are withdrawn to detect the percentage of active ingredient dissolved over time.
- The tablets according to the present invention, when designed to be used to treat inflammatory bowel disease, in principle have to show a good resistance, thanks to the polymeric film resistant to the low pH conditions (intended as <5 to simulate the gastric environment) applied to cover the tablet surface, resistance which last at least for two hours; to target the large intestinal sectors, also the pH condition of 6.4 shown unsuitability to determine a drug leakage from the administration device for a short exposition time and only mediums at pH 7.2 have been able to determine an active ingredient dissolution at a progressive and quite constant rate during a timeframe from 6 to 12 hours; the dissolution percentage obtained with this tablet formulation were below 15% at first hour sampling, below 25% at second hour sampling, then values were in the range 25% to 55% at fourth hour and a dissolution greater than 80% was achieved at 8th hour sampling.
- 2.7 kg of budesonide, 3.0 kg of lecithin (amphiphilic matrix forming material) and 3.0 kg of stearic acid (lipophilic matrix forming material) are mixing after sieving till an homogeneous mixture is obtained; then add 39.0 kg of inert, functional excipients and 9.0 kg of low viscosity hydroxypropylcellulose (binder) and mix for 10 minutes before adding purified water and kneading to a suitable consistence. Then pass the granulate through a rotating granulator equipped with the suitable screen and transfer the granulate to the fluid bed drier to lower the residual moisture content under 3%.
- After a new sieving on the dry, the granulate is added of 9.0 kg of hydroxypropylcellulose (hydrophilic matrix forming material) and the suitable amount of functional excipients (in particular, microcrystalline cellulose, lactose and silicon dioxide) and, after 15 minutes of mixing, magnesium stearate in a suitable quantity to act as lubricant is added.
- After a final blending, tablets of around 300 mg of unitary weight are generated.
- The core are then subjected to be coated with a suspension obtained introducing into a stainless steel container 5.8 kg of Eudragit™ (methacrylate copolymers), 0.6 kg of triethylcitrate and 3.0 kg of dyes and talc, using alcohol as solvent.
- The mean dissolution percentage (as average of six or more tablets) obtained with this tablet formulation were around 10-20% at second hour sampling, in the range 25% to 65% at fourth hour and a dissolution greater than 80% was achieved at 8th hour sampling.
-
-
Component mg/tablet Tablet Budesonide 9.0 Stearic Acid 10.0 Lecithin 10.0 Microcristalline cellulose 156.0 Hydroxypropylcellulose 60.0 Lactose monohydrate 50.0 Silicon dioxide 2.0 Magnesium stearate 3.0 Coating materials Eudragit L100 14.0 Eudragit S100 12.0 Talc 7.9 Titanium dioxiede 4.5 Triethylcitrate 1.6 Alcohol q.s. - According to the present invention, coated tablets individually weighing about 220 mg are obtained.
- The above described dissolution test is performed on the tablets of Example 2.
- The results are the following (indicated as average value):
-
after 2 hours at pH 1 resistant (<5%) after 1 hour at pH 6.4 resistant (<5%) after 2 hours at pH 7.2 15% after 4 hours at pH 7.2 37% after 8 hours at pH 7.2 91% - Budesonide (3.0 kg) is mixed with soybean Lecithin (5.0 kg) till an homogeneous mixture is obtained. Then carnauba wax (2.0 kg) and stearic acid (2.0 kg) sieved through a fine screen are added. After mixing, the powders are added with other functional excipients and kneaded with a binder solution obtained by dissolving medium viscosity polyvinylpirrolidone in water. After drying in a fluid bed and milling throughout a suitable screen, hydroxypropylmethylcellulose (35.0 kg) and other excipients, including magnesium stearate as lubricant, in a suitable quantity are added and the mixture is blended till an homogeneous powder dispersion is obtained.
- The powder mixture is subjected to compression in a rotating tabletting machine and the tablets so obtained are coated in a pan coat with a gastroresistant composition containing Eudragit™, plasticizers, dyes and pigments.
- According to the present example, coated tablets individually weighing around 105 mg are obtained.
- The results of the above described dissolution test are the following (indicated as average value of at least six tablets):
-
after 2 hours at pH 1 resistant (<5%) after 1 hour at pH 6.4 resistant (<5%) after 2 hours at pH 7.2 9% after 4 hours at pH 7.2 28% after 8 hours at pH 7.2 86% - 50 g of diethylene glycol monoethyl ether are homogeneously distributed on 500 g of microcrystalline cellulose; then 100 g of Budesonide are added, mixing to complete homogenization. This mix is further added with 400 g of Budesonide, then dispersed in a blender containing 100 g of carnauba wax and 100 g of stearic acid preheated at a temperature of 60[deg.] C. After kneading for 5 minutes, the mixture is cooled to room temperature and extruded in granules of size below 1 mm. A suitable mixer is loaded with the matrix granules prepared as above and the following amounts of hydrophilic excipients: 1500 g of hydroxypropyl methylcellulose and 500 g of Policarbophil™ are added. The components are mixed until homogeneous dispersion of the matrices, then added with 2450 g of microcrystalline cellulose, 400 g of lactose, 100 g of colloidal silica and 50 g of magnesium stearate. After further 5 minute mixing, the mix is tabletted to unitary weight of 250 mg/tablet.
- Tablets are then subjected to coating using a suspension n containing polyacrylate and poly methacrilate copolymers in addition to other dyes, plasticizers and colouring agents in solvent (ethylic alcohol).
- The results of the dissolution test performed on these coated tablets are the following (indicated as average value of at least six tablets):
-
after 2 hours at pH 1 resistant (<5%) after 1 hour at pH 6.4 resistant (<5%) after 2 hours at pH 7.2 11% after 4 hours at pH 7.2 32% after 8 hours at pH 7.2 76% - 500 g of 5-aminosalicylic-acid and 20 g of octylonium bromide are mixed with 10 g of soy lecithin dissolved in 50 g of a water:ethyl alcohol 1:3 mixture at about 50° C. After homogenization and drying, the granules of the resulting matrix are treated in a kneader with 20 g of carnauba wax and 50 g of stearic acid, heating until homogeneous dispersion, then cold-extruded into small granules. The inert matrix granules are loaded into a mixer in which 30 g of carbopol 971 P and 65 g of hydroxypropyl methylcellulose “are sequentially added.” After a first mixing step for homogeneously dispersing the powders, 60 g of microcrystalline cellulose and 5 g of magnesium stearate are added. After mixing, the final mixture is tabletted to unitary weight of 760 mg/tablet. The resulting tablets are film-coated with cellulose acetophthalate or polymethacrylates and a plasticizer to provide gastric resistance and prevent the early release of product in the stomach.
- The resulting tablets, when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 60 minutes no more than 30%, after 180 minutes no more than 60%, after 5 hours no more than 80%.
- 50 g of diethylene glycol monoethyl ether are homogeneously distributed on 500 g of microcrystalline cellulose; then 100 g of Budesonide are added, mixing to complete homogenization. This mix is further added with 400 g of Budesonide, then dispersed in a blender containing 100 g of carnauba wax and 100 g of stearic acid preheated at a temperature of 60° C. After kneading for 5 minutes, the mixture is cooled to room temperature and extruded in granules of size below 1 mm.
- A suitable mixer is loaded with the matrix granules prepared as above and the following amounts of hydrophilic excipients: 1500 g of hydroxypropyl methylcellulose and 500 g of policarbophil.
- The components are mixed until homogeneous dispersion of the matrices, then added with 2450 g of microcrystalline cellulose, 400 g of lactose, 100 g of colloidal silica and 50 g of magnesium stearate. After further 5 minute mixing, the mix is tabletted to unitary weight of 250 mg/tablet.
- 850 g of metformin are dispersed in a granulator/kneader with 35 g of diethylene glycol monoethyl ether previously melted with 100 g of stearic acid and 55 g of carnauba wax. The system is heated to carry out the granulation of the active ingredient in the inert matrix. The resulting 1040 g of formulation are added with 110 g of hydroxypropyl methylcellulose and 20 g of magnesium stearate.
- The final mixture is tabletted to unitary weight of 1170 mg/tablet equivalent to 850 mg of active ingredient.
- The resulting tablets, when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 60 minutes no more than 35%, after 180 minutes no more than 60%, after 5 hours no more than 80%.
- 120 g of octylonium bromide are dispersed in a granulator/kneader with 30 g of stearic acid and 15 g of beeswax in which 10 g of diethylene glycol monoethylene had previously been melted.
- The system is heated to carry out the granulation of the active ingredient in the inert matrix. The resulting 10 g of formulation are added with 5 g of hydroxypropyl methylcellulose and 5 g of policarbophyl, 2 g of magnesium stearate and 3 g of microcrystalline cellulose.
- The final mixture is tabletted to unitary weight of 200 mg/tablet equivalent to 120 mg of active ingredient.
- The resulting tablets, when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 60 minutes no more than 25%; after 180 minutes no more than 50%; after 5 hours no more than 70%.
- 12 g of diethylene glycol monoethyl ether are loaded on 6 g of microcrystalline cellulose and 6 grams of calcium carbonate, then 100 g of Gabapentin are added and the mixture is homogenized. After that, 800 g of Gabapentin are added which are dispersed in a granulator/kneader with 4.5 g of white wax and 5 g of stearic acid. The system is heated to carry out the granulation of the active ingredient in the inert matrix. The resulting 916.5 g of formulation are added with 39.5 g of hydroxypropyl methylcellulose, 10 g of alginic acid, 11 g of magnesium stearate and 6 g of syloid. The final mixture is tabletted to unitary weight of 1000 mg/tablet equivalent to 900 mg of active ingredient.
- 50 g (25 g) of carbidopa and 200 g (100 g) of levodopa are dispersed in a granulator/kneader with 60 g (30 g) of stearic acid and 30 g (15 g) of yellow wax, in which 10 (5) g of diethylene glycol monoethyl ether had previously been melted.
- The system is heated to carry out the granulation of the active ingredient in the inert matrix. The resulting 340 g (170 g) of formulation are added with 20 g (10 g) of hydroxypropyl methylcellulose, 10 g (5 g) of xantangum, 16 g (8 g) of microcrystalline cellulose, 4 g (2 g) of magnesium stearate.
- The final mixture is tabletted to unitary weight of 400 (200) mg/tablet equivalent to 50 (25) mg of carbidopa and 200 (−100) mg di levodopa.
- 4 g of Nimesulide are solubilised in 50 g of diethylene glycol monoethyl ether, then 100 g of microcrystalline cellulose are added to obtain a homogeneous mixture.
- The resulting mixture is added in a granulator/kneader with 196 g of Nimesulide, 50 g of stearic acid and 25 g of carnauba wax. The system is heated to carry out the granulation of the active ingredient in the inert and amphiphilic matrix system.
- 425 g of the resulting granulate are added with 60 g of hydroxypropyl methylcellulose, 5 g of policarbophil and 10 g of magnesium stearate.
- The final mixture is tabletted to unitary weight of 500 mg/tablet equivalent to 200 mg of active ingredient.
- The resulting tablets, when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 1 hour no more than 25%, after 2 hours no more than 40%, after 4 hours no more than 60%, after 8 hours no more than 90%.
- 500 g of propionyl carnitine are dispersed in a granulator/kneader with 90 g of stearic acid and 40 g of carnauba wax, in which 20 g of diethylene glycol monoethyl ether had previously been melted. The system is heated to carry out the granulation of the active ingredient in the inert/amphiphilic matrix. The resulting 650 g of formulation are added with 60 g of hydroxypropyl methylcellulose and 10 g of magnesium stearate.
- The final mixture is tabletted to unitary weight of 720 mg/tablet equivalent to 500 mg of active ingredient.
- The resulting tablets, when subjected to dissolution test in simulated enteric juice, have shown a release of the active principles having the following profile: after 60 minutes no more than 40%, after 180 minutes no more than 60%, after 4 hours no more than 80%, after 8 hours no more than 90%.
- One kg of Nimesulide is placed in a high rate granulator, pre-heated to about 70°, together with 200 g of cetyl alcohol and 25 g of glycerol palmitostearate the mixture is kneaded for about 15 minutes and stirred while decreasing temperature to about 30° C. The resulting inert matrix is added, keeping stirring and kneading during cooling, with 50 g of soy lecithin and 50 g of ethylene glycol monoethyl ether. The granulate is extruded through a metallic screen of suitable size and mixed with 50 g of hydroxypropyl methylcellulose, 1320 kg of maltodextrins, 2 kg of lactose-cellulose mixture, 50 g of colloidal silica, 40 g of aspartame, 150 g of citric acid, 75 g of flavour and 65 g of magnesium stearate. The final mixture is tabletted to unitary weight of about 500 mg, having hardness suitable for being dissolved in the mouth and a pleasant taste.
- Operating as in the preceding Example, chewable tablets are prepared replacing dextrin with mannitol and the lactose-cellulose mixture with xylitol. The resulting tablets have pleasant taste and give upon chewing a sensation of freshness enhancing the flavour.
- Operating as described in Example I, but with the following components:
-
active ingredient: ibuprofen mg 100 lipophilic/inert matrix component: mg 15 cetyl alcohol amphiphilic matrix component: mg 8 soy lecithin hydrophilic matrix components: mannitol mg 167 maltodextrins mg 150 methylhydroxypropylcellulose mg 30 adjuvants: aspartame mg 15 flavour mg 5 colloidal silica mg 5 magnesium stearate mg 5 - 500 mg unitary weight tablets are obtained, which undergo progressive erosion upon buccal administration, and effectively mask the bitter, irritating taste of the active ingredient.
- Operating as described in Example I, but with the following components:
-
active ingredient: diclofenac sodium mg 25 lipophilic/inert matrix component: mg 5 cetyl alcohol glycerol palmitostearate mg 5 amphiphilic matrix component: mg 7 soy lecithin hydrophilic matrix components: xylitol mg 168 maltodextrins mg 150 hydroxypropylmethylcellulose mg 20 adjuvants: aspartame mg 5 flavour mg 5 colloidal silica mg 5 magnesium stearate mg 5 - 400 mg unitary weight tablets are obtained, which undergo progressive erosion upon buccal administration, and effectively mask the irritating taste of the active ingredient.
- Operating as described in Example I, but with the following components:
-
active ingredient: chlorhexidine mg 2.5 lipophilic/inert matrix component: mg 0.5 cetyl alcohol glycerol palmitostearate mg 0.5 amphiphilic matrix component: mg 0.3 diethylene glycol monoethyl ether hydrophilic matrix components: xylitol mg 38 maltodextrins mg 96 hydroxypropyl methylcellulose mg 10 adjuvants: aspartame mg 3 flavour mg 5 colloidal silica mg 2 magnesium stearate mg 2 - 150 mg unitary weight tablets are obtained, which undergo progressive erosion upon buccal administration, and effectively mask the irritating taste of the active ingredient.
- One Kg of Nimesulide is placed in a high rate granulator, pre-heated to about 70°, together with g 125 of cetyl alcohol: the mixture is kneaded for about 15 minutes and stirred while decreasing temperature to about 30° C., then added with g 30 of lecithin. The resulting matrix is then extruded through a metallic screen of suitable size and mixed with 2.415 kg of lactose, 1.0 kg of maltodextrins, 50 g of hydroxypropyl methylcellulose, 50 g of colloidal silica, 40 g of aspartame, 150 g of citric acid, 75 g of flavour and 65 g of magnesium stearate. The final mixture is tabletted to about 500 mg tablets, having hardness suitable for being dissolved in the mouth and pleasant taste.
Claims (1)
1. A controlled release oral pharmaceutical composition, comprising:
(1) budesonide in an amount effective for treatment of inflammatory bowel disease, and
(2) means for topically delivering in the gastrointestinal tract said effective amount of budesonide.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/462,430 US20120220559A1 (en) | 1999-06-14 | 2012-05-02 | Controlled Release and Taste Masking Oral Pharmaceutical Composition |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1999MI001317A ITMI991317A1 (en) | 1999-06-14 | 1999-06-14 | THERAPEUTIC SYSTEMS WITH MODIFIED RELEASE FOR ORAL PHARMACEUTICAL FORM |
ITMI99A001317 | 1999-06-14 | ||
IT2000MI000422A IT1317871B1 (en) | 2000-03-03 | 2000-03-03 | Controlled release and taste masking oral compositions comprising active ingredient incorporated in a matrix structure |
ITMI2000A000422 | 2000-03-03 | ||
PCT/EP2000/005356 WO2000076478A1 (en) | 1999-06-14 | 2000-06-09 | Controlled release and taste masking oral pharmaceutical compositions |
US953201A | 2001-12-12 | 2001-12-12 | |
US12/210,969 US8029823B2 (en) | 1999-06-14 | 2008-09-15 | Controlled release and taste masking oral pharmaceutical composition |
US13/249,839 US20120021053A1 (en) | 1999-06-14 | 2011-09-30 | Controlled release and taste-masking oral pharmaceutical composition |
US13/462,430 US20120220559A1 (en) | 1999-06-14 | 2012-05-02 | Controlled Release and Taste Masking Oral Pharmaceutical Composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/249,839 Continuation US20120021053A1 (en) | 1999-06-14 | 2011-09-30 | Controlled release and taste-masking oral pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120220559A1 true US20120220559A1 (en) | 2012-08-30 |
Family
ID=26331662
Family Applications (20)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/009,532 Expired - Lifetime US7431943B1 (en) | 1999-06-14 | 2000-06-09 | Controlled release and taste masking oral pharmaceutical compositions |
US11/268,500 Expired - Lifetime US7410651B2 (en) | 1999-06-14 | 2005-11-08 | Controlled release and taste masking oral pharmaceutical composition |
US11/378,378 Expired - Lifetime US7410652B2 (en) | 1999-06-14 | 2006-03-20 | Controlled release and taste masking oral pharmaceutical composition |
US12/210,969 Ceased US8029823B2 (en) | 1999-06-14 | 2008-09-15 | Controlled release and taste masking oral pharmaceutical composition |
US13/249,839 Abandoned US20120021053A1 (en) | 1999-06-14 | 2011-09-30 | Controlled release and taste-masking oral pharmaceutical composition |
US13/462,430 Abandoned US20120220559A1 (en) | 1999-06-14 | 2012-05-02 | Controlled Release and Taste Masking Oral Pharmaceutical Composition |
US13/462,409 Expired - Lifetime US8293273B2 (en) | 1999-06-14 | 2012-05-02 | Controlled release and taste masking oral pharmaceutical composition |
US13/477,592 Expired - Fee Related USRE43799E1 (en) | 1999-06-14 | 2012-05-22 | Controlled release and taste masking oral pharmaceutical composition |
US13/597,867 Abandoned US20120321710A1 (en) | 1999-06-14 | 2012-08-29 | Controlled Release and Taste Masking Oral Pharmaceutical Composition |
US13/617,138 Expired - Fee Related US8784888B2 (en) | 1999-06-14 | 2012-09-14 | Controlled release and taste masking oral pharmaceutical composition |
US13/660,308 Abandoned US20130053360A1 (en) | 1999-06-14 | 2012-10-25 | Controlled release and taste masking oral pharmaceutical composition |
US14/308,279 Expired - Lifetime US9320716B2 (en) | 1999-06-14 | 2014-06-18 | Controlled release and taste masking oral pharmaceutical compositions |
US14/308,305 Expired - Fee Related US9532954B2 (en) | 1999-06-14 | 2014-06-18 | Controlled release and taste masking oral pharmaceutical compositions |
US14/514,967 Abandoned US20150056279A1 (en) | 1999-06-14 | 2014-10-15 | Controlled Release and Taste Masking Oral Pharmaceutical Compositions |
US15/369,296 Expired - Fee Related US10064878B2 (en) | 1999-06-14 | 2016-12-05 | Controlled release and taste masking oral pharmaceutical compositions |
US15/646,330 Expired - Fee Related US10143698B2 (en) | 1999-06-14 | 2017-07-11 | Controlled release and taste masking oral pharmaceutical compositions |
US15/646,538 Expired - Fee Related US10105374B2 (en) | 1999-06-14 | 2017-07-11 | Controlled release and taste masking oral pharmaceutical compositions |
US16/132,718 Abandoned US20190015428A1 (en) | 1999-06-14 | 2018-09-17 | Controlled release and taste masking oral pharmaceutical compositions |
US16/139,672 Abandoned US20190022112A1 (en) | 1999-06-14 | 2018-09-24 | Controlled release and taste masking oral pharmaceutical compositions |
US16/234,951 Abandoned US20190134061A1 (en) | 1999-06-14 | 2018-12-28 | Controlled release and taste masking oral pharmaceutical compositions |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/009,532 Expired - Lifetime US7431943B1 (en) | 1999-06-14 | 2000-06-09 | Controlled release and taste masking oral pharmaceutical compositions |
US11/268,500 Expired - Lifetime US7410651B2 (en) | 1999-06-14 | 2005-11-08 | Controlled release and taste masking oral pharmaceutical composition |
US11/378,378 Expired - Lifetime US7410652B2 (en) | 1999-06-14 | 2006-03-20 | Controlled release and taste masking oral pharmaceutical composition |
US12/210,969 Ceased US8029823B2 (en) | 1999-06-14 | 2008-09-15 | Controlled release and taste masking oral pharmaceutical composition |
US13/249,839 Abandoned US20120021053A1 (en) | 1999-06-14 | 2011-09-30 | Controlled release and taste-masking oral pharmaceutical composition |
Family Applications After (14)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/462,409 Expired - Lifetime US8293273B2 (en) | 1999-06-14 | 2012-05-02 | Controlled release and taste masking oral pharmaceutical composition |
US13/477,592 Expired - Fee Related USRE43799E1 (en) | 1999-06-14 | 2012-05-22 | Controlled release and taste masking oral pharmaceutical composition |
US13/597,867 Abandoned US20120321710A1 (en) | 1999-06-14 | 2012-08-29 | Controlled Release and Taste Masking Oral Pharmaceutical Composition |
US13/617,138 Expired - Fee Related US8784888B2 (en) | 1999-06-14 | 2012-09-14 | Controlled release and taste masking oral pharmaceutical composition |
US13/660,308 Abandoned US20130053360A1 (en) | 1999-06-14 | 2012-10-25 | Controlled release and taste masking oral pharmaceutical composition |
US14/308,279 Expired - Lifetime US9320716B2 (en) | 1999-06-14 | 2014-06-18 | Controlled release and taste masking oral pharmaceutical compositions |
US14/308,305 Expired - Fee Related US9532954B2 (en) | 1999-06-14 | 2014-06-18 | Controlled release and taste masking oral pharmaceutical compositions |
US14/514,967 Abandoned US20150056279A1 (en) | 1999-06-14 | 2014-10-15 | Controlled Release and Taste Masking Oral Pharmaceutical Compositions |
US15/369,296 Expired - Fee Related US10064878B2 (en) | 1999-06-14 | 2016-12-05 | Controlled release and taste masking oral pharmaceutical compositions |
US15/646,330 Expired - Fee Related US10143698B2 (en) | 1999-06-14 | 2017-07-11 | Controlled release and taste masking oral pharmaceutical compositions |
US15/646,538 Expired - Fee Related US10105374B2 (en) | 1999-06-14 | 2017-07-11 | Controlled release and taste masking oral pharmaceutical compositions |
US16/132,718 Abandoned US20190015428A1 (en) | 1999-06-14 | 2018-09-17 | Controlled release and taste masking oral pharmaceutical compositions |
US16/139,672 Abandoned US20190022112A1 (en) | 1999-06-14 | 2018-09-24 | Controlled release and taste masking oral pharmaceutical compositions |
US16/234,951 Abandoned US20190134061A1 (en) | 1999-06-14 | 2018-12-28 | Controlled release and taste masking oral pharmaceutical compositions |
Country Status (17)
Country | Link |
---|---|
US (20) | US7431943B1 (en) |
EP (1) | EP1183014B1 (en) |
JP (3) | JP4790950B2 (en) |
CN (1) | CN1173695C (en) |
AT (1) | ATE251449T1 (en) |
AU (1) | AU5680100A (en) |
CA (1) | CA2377301C (en) |
DE (1) | DE60005819T2 (en) |
DK (1) | DK1183014T3 (en) |
ES (1) | ES2208349T3 (en) |
HK (1) | HK1046244B (en) |
MX (1) | MXPA01012889A (en) |
NO (1) | NO331642B1 (en) |
PT (1) | PT1183014E (en) |
RU (1) | RU2246293C2 (en) |
TR (1) | TR200200562T2 (en) |
WO (1) | WO2000076478A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120021052A1 (en) * | 1999-06-14 | 2012-01-26 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US8545811B2 (en) | 2010-03-04 | 2013-10-01 | Cosmo Technologies Ltd. | Solid composition for the oral administration of dyes and diagnostic use thereof |
US9320716B2 (en) | 1999-06-14 | 2016-04-26 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical compositions |
US10154964B2 (en) | 2011-09-07 | 2018-12-18 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI991316A1 (en) * | 1999-06-14 | 2000-12-14 | Cip Ninety Two 92 S A | ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF MESALAZINE |
CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
ITMI20011337A1 (en) | 2001-06-26 | 2002-12-26 | Farmatron Ltd | ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF THE ACTIVE SUBSTANCE |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
ITMI20012366A1 (en) * | 2001-11-09 | 2003-05-09 | Farmatron Ltd | THERAPEUTIC SYSTEMS STABILIZED WITH IMMEDIATE RELEASE AND / OR MODIFIED FOR THE ORAL ADMINISTRATION OF ACTIVE AND / OR EXCIPIENT PRINCIPLES AND / OR WINGS |
TWI252111B (en) * | 2001-12-14 | 2006-04-01 | Solvay Pharm Gmbh | Matrix film tablet with controlled release of a natural mixture of conjugated estrogens |
FR2838349B1 (en) * | 2002-04-15 | 2004-06-25 | Laurence Paris | LIQUID COMPOSITIONS FOR SUSTAINED RELEASE SOFT CAPSULES AND PROCESS FOR PRODUCING THE SAME |
EP1513504A1 (en) * | 2002-06-07 | 2005-03-16 | Ranbaxy Laboratories, Ltd. | Sustained release oral dosage forms of gabapentin |
US20040086566A1 (en) * | 2002-11-04 | 2004-05-06 | Alpharma, Inc. | Waxy matrix dosage forms |
FR2852843B1 (en) * | 2003-03-24 | 2008-05-23 | Karim Ioualalen | GALENIC SYSTEM FOR MASKING TASTE |
WO2005009432A1 (en) * | 2003-07-29 | 2005-02-03 | Ranbaxy Laboratories Limited | New dosage regimen in case of concurrent intake of gabapentin with food and an increased oral bioavailability therewith |
WO2005072717A1 (en) * | 2004-01-29 | 2005-08-11 | Dainippon Sumitomo Pharma Co., Ltd. | Biguanide preparation for internal use |
ITMI20040187A1 (en) * | 2004-02-06 | 2004-05-06 | Cosmo Spa | PHARMACEUTICAL OR DIETETIC COMPOSITIONS BASED ON SHORT CHAIN FATTY ACIDS AND COMPLEX SUGARS FOR INTESTINAL DYSFUNCTIONS |
ITMI20041295A1 (en) * | 2004-06-25 | 2004-09-25 | Cosmo Spa | ORAL ANTI-MICROBIAL PHARMACEUTICAL COMPOSITIONS |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
ES2288117B1 (en) * | 2006-05-08 | 2008-12-01 | Combino Pharm, S.L. | SOLID PHARMACEUTICAL COMPOSITION OF GABAPENTINA. |
CA2657769C (en) * | 2006-07-19 | 2014-11-18 | The Board Of Regents Of The University Of Texas System | Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease |
CA2663548A1 (en) * | 2006-09-12 | 2008-03-20 | Cosmo Technologies Ltd | Pharmaceutical compositions for the oral or rectal administration of protein substances |
FR2913884A1 (en) * | 2007-03-21 | 2008-09-26 | Oralance Pharma Sa | NON-IONIZABLE HYDROPHOBIC GALENIC SYSTEM |
DE102007041588A1 (en) * | 2007-09-01 | 2009-03-05 | Lts Lohmann Therapie-Systeme Ag | Medicament, useful for controlled, continuous or sudden release of medicinal substances in the medicament, comprises harmless, alcoholic fermentation enabled yeast, carbohydrates and water in a separate compartment |
CA2722295C (en) * | 2008-04-29 | 2019-01-15 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
EP2334287A4 (en) | 2008-08-20 | 2013-12-25 | Univ Texas | Hot-melt extrusion of modified release multi-particulates |
CA2638240C (en) * | 2008-08-29 | 2010-02-02 | Alexander Macgregor | Method of treating dysglycemia and glucose excursions |
AU2008243202B2 (en) * | 2008-11-11 | 2015-08-20 | Cosmo Technologies Ltd | Oral antimicrobial pharmaceutical compositions |
US9314444B2 (en) | 2009-01-12 | 2016-04-19 | Biokier, Inc. | Composition and method for treatment of NASH |
EA022631B1 (en) * | 2009-01-12 | 2016-02-29 | Байокир Инк. | Composition comprising butyric acid or glutamine, and method of treating a condition affected by increasing glucose levels in a subject |
US20150224081A1 (en) * | 2009-01-12 | 2015-08-13 | Biokier, Inc. | Composition and method for treatment of diabetes |
US9006288B2 (en) | 2009-01-12 | 2015-04-14 | Biokier, Inc. | Composition and method for treatment of diabetes |
US8945615B2 (en) | 2009-02-17 | 2015-02-03 | Mylan Pharmaceuticals Inc. | Controlled release budesonide minitablets |
US8945616B2 (en) | 2009-02-17 | 2015-02-03 | Mylan Pharmaceuticals Inc. | Controlled release budesonide minitablets |
DE102009012788A1 (en) * | 2009-03-13 | 2010-09-30 | J. Rettenmaier & Söhne Gmbh + Co. Kg | Compressible tablet material with oily agent, tablet and method and apparatus for their preparation |
EP2432455B1 (en) | 2009-05-18 | 2014-11-12 | Sigmoid Pharma Limited | Composition comprising oil drops |
GB0909680D0 (en) | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
WO2010144865A2 (en) | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
EP2496217B1 (en) * | 2009-08-24 | 2019-03-27 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Direct compression tablets of otilonium |
US9301938B2 (en) | 2009-09-23 | 2016-04-05 | Biokier, Inc. | Composition and method for treatment of diabetes |
US9463163B2 (en) | 2009-10-16 | 2016-10-11 | Sun Pharmaceutical Industries Limited | Delayed release pharmaceutical composition of mesalamine |
CN107033368A (en) | 2009-11-09 | 2017-08-11 | 聚光灯技术合伙有限责任公司 | fragmentation hydrogel |
US9700650B2 (en) | 2009-11-09 | 2017-07-11 | Spotlight Technology Partners Llc | Polysaccharide based hydrogels |
CN103429739B (en) | 2010-05-12 | 2018-11-13 | 哥伦比亚大学纽约管理委员会 | Prepare the method generated with the enteroendocrine cell of excreting insulin |
WO2011154975A2 (en) | 2010-06-08 | 2011-12-15 | Cadila Healthcare Limited | Pharmaceutical compositions of metformin |
WO2012013495A1 (en) | 2010-07-29 | 2012-02-02 | Cosmo Technologies Ltd. | Pharmaceutical and/or dietary compositions based on short chain fatty acids |
IT1402047B1 (en) * | 2010-10-19 | 2013-08-28 | Cross Pharma Sa | USE OF MEXIPROSTIL IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES |
EP2446877A1 (en) * | 2010-10-29 | 2012-05-02 | Roquette Frères | Modified starch derivative-based matrix for colon targeting |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
AU2012250877B2 (en) | 2011-05-02 | 2016-07-21 | Biokier, Inc. | Composition and method for treatment of diabetes |
AT511581A1 (en) * | 2011-05-26 | 2012-12-15 | G L Pharma Gmbh | ORAL RETARDANT FORMULATION |
AU2011248587A1 (en) * | 2011-11-09 | 2013-05-23 | Cosmo Technologies Ltd | Controlled release and taste masking oral pharmaceutical composition |
US10722458B2 (en) * | 2011-12-02 | 2020-07-28 | Pegasus Laboratories, Inc. | Amphipathic lipid-based sustained release compositions |
MX351453B (en) * | 2011-12-02 | 2017-10-16 | Pegasus Laboratories Inc | Amphipathic lipid-based sustained release compositions. |
AU2013220464A1 (en) | 2012-02-13 | 2014-09-04 | Cosmo Technologies Limited | Method for treating intestinal diseases presenting at least one inflammatory component |
CN104302278B (en) | 2012-03-29 | 2018-08-21 | 塞拉拜姆有限责任公司 | The active stomach and intestine locus specificity Oral vaccination preparation on ileum and appendix |
EP2722058A1 (en) | 2012-10-19 | 2014-04-23 | Cosmo Technologies Ltd | Solid oral composition containing dyes for use in endoscopic diagnosis |
CA2897878A1 (en) * | 2013-01-14 | 2014-07-17 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
SG11201505245XA (en) * | 2013-01-14 | 2015-08-28 | Infirst Healthcare Ltd | Compositions and methods for treating severe pain |
SG11201505243PA (en) * | 2013-02-04 | 2015-08-28 | Infirst Healthcare Ltd | Compositions and methods for treating chronic inflammation and inflammatory diseases |
CN105120847B (en) | 2013-03-14 | 2018-12-28 | 塞拉拜姆有限责任公司 | The delivering of the targeting gastrointestinal tract of probiotics and/or therapeutic agent |
US9240075B2 (en) | 2013-03-15 | 2016-01-19 | Daqri, Llc | Campaign optimization for experience content dataset |
CN103417507B (en) * | 2013-08-23 | 2015-12-02 | 王显著 | Budesonide pharmaceutical composition |
US20150073057A1 (en) | 2013-09-06 | 2015-03-12 | Biokier, Inc. | Composition and method for treatment of diabetes |
ITMI20131578A1 (en) * | 2013-09-25 | 2015-03-26 | Giellepi S P A | SUBSTANCE AND FORMULATION FOR THE TREATMENT OF CHRONIC INTESTINAL INFLAMMATORY DISEASES |
IN2013MU03373A (en) * | 2013-10-25 | 2015-07-17 | Cadila Healthcare Ltd | |
WO2015071812A1 (en) | 2013-11-18 | 2015-05-21 | Wockhardt Limited | Solid oral modified-release composition comprising budesonide or salt thereof |
GB2525227B (en) | 2014-04-16 | 2016-09-14 | Jaguar Land Rover Ltd | Bumper assembly method and apparatus |
US10487314B2 (en) | 2014-06-26 | 2019-11-26 | The Trustees Of Columbia University In The City Of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
EP3006453A1 (en) * | 2014-10-08 | 2016-04-13 | Cosmo Technologies Ltd. | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
CN104523717A (en) * | 2015-01-06 | 2015-04-22 | 西南大学 | Simethicone otilonium bromide chewable tablets and preparing method thereof |
WO2017058881A1 (en) | 2015-09-28 | 2017-04-06 | The Trustees Of Columbia University In The City Of New York | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma |
US20200061212A1 (en) | 2016-11-28 | 2020-02-27 | Cosmo Technologies Ltd. | Solid oral composition containing dyes |
US20180118747A1 (en) * | 2017-01-03 | 2018-05-03 | Thermolife International, Llc | Method of isolating theacrine and composition comprising theacrine |
CA3073195A1 (en) | 2017-08-15 | 2019-02-21 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
KR20200086285A (en) | 2017-11-10 | 2020-07-16 | 코스모 테크놀러지스 리미티드 | Oral rifamycin SV composition |
EP3501503A1 (en) * | 2017-12-22 | 2019-06-26 | Cosmo Technologies Ltd. | Solid delivery composition |
EP3613414A1 (en) | 2018-08-24 | 2020-02-26 | Dr. Falk Pharma Gmbh | Pellets with multilayer structure for delayed release of the drug in the distal colon |
CN110585164A (en) * | 2019-10-08 | 2019-12-20 | 苏州弘森药业股份有限公司 | Method for preparing esomeprazole magnesium sodium bicarbonate capsule |
WO2022254456A1 (en) * | 2021-06-01 | 2022-12-08 | Nbi Biosciences Pvt Ltd | Microbial-triggered oral intestinal drug delivery formulation and method of preparation thereof |
US11896719B2 (en) | 2022-01-24 | 2024-02-13 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681584A (en) * | 1993-04-23 | 1997-10-28 | Ciba-Geigy Corporation | Controlled release drug delivery device |
US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133863A (en) | 1961-03-10 | 1964-05-19 | Strong Cobb Arner Inc | Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums |
US3138525A (en) | 1961-06-16 | 1964-06-23 | Hoffmann La Roche | Castor wax-amprotropine-resin compositions |
US3800051A (en) | 1970-09-21 | 1974-03-26 | Dow Chemical Co | Reducing serum cholesterol with certain substituted phenols |
US3965256A (en) | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
IE59287B1 (en) | 1984-02-10 | 1994-02-09 | Benzon Pharma As | Diffusion coated multiple-units dosage form |
US4608248A (en) | 1985-11-08 | 1986-08-26 | Warner-Lambert Company | Process for time-controlled release of active ingredients |
JPS6348226A (en) * | 1986-08-14 | 1988-02-29 | Ono Pharmaceut Co Ltd | Slowly releasing solid preparation for oral administration |
US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
IL92343A0 (en) | 1988-12-20 | 1990-07-26 | Gist Brocades Nv | Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them |
US5643602A (en) * | 1989-11-22 | 1997-07-01 | Astra Aktiebolag | Oral composition for the treatment of inflammatory bowel disease |
IT1246382B (en) | 1990-04-17 | 1994-11-18 | Eurand Int | METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON |
JP3011752B2 (en) * | 1990-10-23 | 2000-02-21 | フロイント産業株式会社 | Sustained-release preparation and method for producing the same |
US5183815A (en) | 1991-01-22 | 1993-02-02 | Merck & Co., Inc. | Bone acting agents |
WO1992016214A1 (en) | 1991-03-15 | 1992-10-01 | Norwich Eaton Pharmaceuticals Inc. | The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d) |
US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
TW209174B (en) * | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
DK0587744T3 (en) | 1991-05-28 | 2003-10-20 | Mcneil Ppc Inc | Chewable composition for release of a drug |
US5534501A (en) * | 1991-06-04 | 1996-07-09 | A Et S Biovecteurs | Particle for use as a milk fat globule substitute, composition containing same and process for the preparation of said particle |
IT1250654B (en) | 1991-07-08 | 1995-04-21 | Farcon Ag | METHOD FOR THE PREPARATION OF ORAL PHARMACEUTICAL FORMS WITH EXTENDED RELEASE CONTAINING ACTIVE SUBSTANCES SOLUBILITY DEPENDENT ON THE PH VALUE. |
DE4131562A1 (en) | 1991-09-18 | 1993-03-25 | Medac Klinische Spezialpraep | SOLID LIPID PARTICLE SOLID LIPID NANOSPHERES (SLN) |
WO1995016451A1 (en) | 1992-06-22 | 1995-06-22 | Franck Arno Gouchet | Tablets for the controlled release of 4-asa |
US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
GB9224855D0 (en) | 1992-11-27 | 1993-01-13 | Smithkline Beecham Plc | Pharmaceutical compositions |
RU95115547A (en) * | 1993-01-08 | 1997-06-10 | Астра Актиеболаг (SE) | Steroid compounds, methods of their synthesis and pharmaceutical preparation |
US5686105A (en) * | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
AU685262B2 (en) * | 1994-03-30 | 1998-01-15 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
US5447729A (en) | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
WO1995028963A1 (en) | 1994-04-22 | 1995-11-02 | Yamanouchi Pharmaceutical Co., Ltd. | Colon-specific drug release system |
EP0758329A1 (en) * | 1994-05-05 | 1997-02-19 | MERCK SHARP & DOHME LTD. | Morpholine derivatives and their use as antagonists of tachikinins |
US5849327A (en) | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
IL129547A (en) * | 1994-10-26 | 2001-01-11 | Novartis Ag | Pharmaceutical compositions comprising a macrolide and an acid |
IL116674A (en) | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
SI9500173B (en) | 1995-05-19 | 2002-02-28 | Lek, | Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application |
US5863910A (en) | 1996-01-12 | 1999-01-26 | Bolonick; Joel | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
GB9613858D0 (en) | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
CN1088584C (en) | 1996-08-02 | 2002-08-07 | 久光制药株式会社 | Capsules for oral preparations and capsule preparations for oral administration |
US5891474A (en) * | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
BRPI9802144B1 (en) | 1997-05-30 | 2017-03-28 | Ezequiel Mayorga Jorge | optimized multi-layer osmotic device |
NZ503086A (en) | 1997-08-29 | 2002-03-01 | Upjohn Co | An orally administrable pharmaceutical composition comprising an inner core and two outer layers, which render it substantially free of unpleasant tastes |
DE29717252U1 (en) | 1997-09-26 | 1998-02-19 | Falk Pharma Gmbh | Drug kit consisting of a budesonide-containing and an ursodeoxycholic acid-containing drug for the treatment of cholestatic liver diseases |
IL135258A0 (en) * | 1997-09-26 | 2001-05-20 | Noven Pharma | Bioadhesive compositions and methods for topical administration of active agents |
US5965167A (en) | 1997-10-07 | 1999-10-12 | Sanghvi; Pradeepkumar P. | Dosage units |
US6607751B1 (en) | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
IT1298575B1 (en) | 1998-02-06 | 2000-01-12 | Vectorpharma Int | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF NANOPARTICLES INCLUDING LIPID SUBSTANCES AND ANTIPHILIC SUBSTANCES AND RELATED PROCESS OF |
US6239120B1 (en) * | 1998-03-17 | 2001-05-29 | Pharmalink Ab | Method and means for treating glomerulonephritis |
CA2274943A1 (en) | 1998-06-17 | 1999-12-17 | Stephen L. Wolman | Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof |
DE19849737A1 (en) | 1998-10-28 | 2000-05-04 | Falk Pharma Gmbh | Combination agent for the treatment of inflammatory bowel disease |
ATE251449T1 (en) | 1999-06-14 | 2003-10-15 | Cosmo Spa | FLAVOR-MASKED ORAL PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED DELIVERY |
ITMI991316A1 (en) | 1999-06-14 | 2000-12-14 | Cip Ninety Two 92 S A | ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF MESALAZINE |
US8895064B2 (en) * | 1999-06-14 | 2014-11-25 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US6363635B1 (en) | 1999-10-22 | 2002-04-02 | Superior Bronze Corporation Of America | Memorial markers and method for producing the same |
JP4159217B2 (en) | 1999-12-15 | 2008-10-01 | 花王株式会社 | Topical skin preparation |
ITMI20012599A1 (en) | 2001-12-11 | 2003-06-11 | Cosmo Spa | PHARMACEUTICAL COMPOSITIONS FOR THE ORAL ADMINISTRATION OF HEPARINE OR DERIVATIVES, USEFUL FOR THERAPY OF INFLAMMATORY DISEASES OF THE INT |
DE10214002A1 (en) | 2002-03-27 | 2003-10-09 | Roehm Gmbh | Pharmaceutical formulation for the active substance budesonide |
GB0222612D0 (en) * | 2002-09-30 | 2002-11-06 | Univ Gent | Controlled delivery system for bioactive substances |
US20060188563A1 (en) | 2003-03-27 | 2006-08-24 | Hisamitsu Pharmaceutical Co., Inc. | Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis |
DE102004043863A1 (en) | 2004-09-10 | 2006-03-16 | Nitec Pharma Ag | Tablets with local and time-controlled drug release in the gastrointestinal tract |
US7715806B2 (en) | 2004-10-06 | 2010-05-11 | Broadcom Corporation | Method and system for diversity processing including using dedicated pilot method for closed loop |
WO2008033124A1 (en) | 2006-09-13 | 2008-03-20 | The Procter & Gamble Company | Methods of treatment for ulcerative colitis |
JP5132416B2 (en) | 2008-05-08 | 2013-01-30 | キヤノン株式会社 | Image processing apparatus and control method thereof |
DE502008002621D1 (en) | 2008-07-21 | 2011-03-31 | Falk Pharma Gmbh | Pharmaceutical formulation for the treatment of the upper digestive tract |
EP2298321A1 (en) | 2009-08-26 | 2011-03-23 | Nordic Pharma | Novel pharmaceutical compositions for treating IBD |
IT1398643B1 (en) | 2010-03-04 | 2013-03-08 | Cosmo Technologies Ltd | SOLID COMPOSITION FOR ORAL ADMINISTRATION OF DYES, AND DIAGNOSTIC USE OF THE SAME |
US8787888B2 (en) * | 2012-08-29 | 2014-07-22 | Facebook, Inc. | Sharing location information during a communication session |
-
2000
- 2000-06-09 AT AT00942044T patent/ATE251449T1/en active
- 2000-06-09 DE DE60005819T patent/DE60005819T2/en not_active Expired - Lifetime
- 2000-06-09 PT PT00942044T patent/PT1183014E/en unknown
- 2000-06-09 CN CNB008088942A patent/CN1173695C/en not_active Expired - Lifetime
- 2000-06-09 DK DK00942044T patent/DK1183014T3/en active
- 2000-06-09 AU AU56801/00A patent/AU5680100A/en not_active Abandoned
- 2000-06-09 RU RU2002100367/15A patent/RU2246293C2/en active
- 2000-06-09 ES ES00942044T patent/ES2208349T3/en not_active Expired - Lifetime
- 2000-06-09 EP EP00942044A patent/EP1183014B1/en not_active Expired - Lifetime
- 2000-06-09 US US10/009,532 patent/US7431943B1/en not_active Expired - Lifetime
- 2000-06-09 TR TR2002/00562T patent/TR200200562T2/en unknown
- 2000-06-09 CA CA002377301A patent/CA2377301C/en not_active Expired - Lifetime
- 2000-06-09 WO PCT/EP2000/005356 patent/WO2000076478A1/en active IP Right Grant
- 2000-06-09 JP JP2001502812A patent/JP4790950B2/en not_active Expired - Lifetime
- 2000-06-09 MX MXPA01012889A patent/MXPA01012889A/en active IP Right Grant
-
2001
- 2001-12-14 NO NO20016108A patent/NO331642B1/en not_active IP Right Cessation
-
2002
- 2002-10-30 HK HK02107843.2A patent/HK1046244B/en not_active IP Right Cessation
-
2005
- 2005-11-08 US US11/268,500 patent/US7410651B2/en not_active Expired - Lifetime
-
2006
- 2006-03-20 US US11/378,378 patent/US7410652B2/en not_active Expired - Lifetime
-
2008
- 2008-09-15 US US12/210,969 patent/US8029823B2/en not_active Ceased
-
2011
- 2011-01-04 JP JP2011000091A patent/JP5279850B2/en not_active Expired - Lifetime
- 2011-01-04 JP JP2011000092A patent/JP5279851B2/en not_active Expired - Lifetime
- 2011-09-30 US US13/249,839 patent/US20120021053A1/en not_active Abandoned
-
2012
- 2012-05-02 US US13/462,430 patent/US20120220559A1/en not_active Abandoned
- 2012-05-02 US US13/462,409 patent/US8293273B2/en not_active Expired - Lifetime
- 2012-05-22 US US13/477,592 patent/USRE43799E1/en not_active Expired - Fee Related
- 2012-08-29 US US13/597,867 patent/US20120321710A1/en not_active Abandoned
- 2012-09-14 US US13/617,138 patent/US8784888B2/en not_active Expired - Fee Related
- 2012-10-25 US US13/660,308 patent/US20130053360A1/en not_active Abandoned
-
2014
- 2014-06-18 US US14/308,279 patent/US9320716B2/en not_active Expired - Lifetime
- 2014-06-18 US US14/308,305 patent/US9532954B2/en not_active Expired - Fee Related
- 2014-10-15 US US14/514,967 patent/US20150056279A1/en not_active Abandoned
-
2016
- 2016-12-05 US US15/369,296 patent/US10064878B2/en not_active Expired - Fee Related
-
2017
- 2017-07-11 US US15/646,330 patent/US10143698B2/en not_active Expired - Fee Related
- 2017-07-11 US US15/646,538 patent/US10105374B2/en not_active Expired - Fee Related
-
2018
- 2018-09-17 US US16/132,718 patent/US20190015428A1/en not_active Abandoned
- 2018-09-24 US US16/139,672 patent/US20190022112A1/en not_active Abandoned
- 2018-12-28 US US16/234,951 patent/US20190134061A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681584A (en) * | 1993-04-23 | 1997-10-28 | Ciba-Geigy Corporation | Controlled release drug delivery device |
US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
Non-Patent Citations (3)
Title |
---|
B.R. D'Haens et al. "Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX 9 mg extended-release tablets in patiens wiht active left-sided ulcerative colitis"; pp153-160; Journal of Crohn's and Colitis (2010). * |
GEN|News Highlights: Positive Phase III Data Leads Cosmo to Project U.S. and EU Filing for UC Drug in 2011; Nov. 8, 2010. * |
Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in Tavelers' Diarrhea; Dec. 30, 2009. * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9592203B2 (en) | 1999-06-14 | 2017-03-14 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US9132093B2 (en) * | 1999-06-14 | 2015-09-15 | Cosmo Technologies Limited | Controlled release and taste making oral pharmaceutical composition |
US20120021052A1 (en) * | 1999-06-14 | 2012-01-26 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US10052286B2 (en) | 1999-06-14 | 2018-08-21 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US9737489B2 (en) | 1999-06-14 | 2017-08-22 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US9192581B2 (en) | 1999-06-14 | 2015-11-24 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US9320716B2 (en) | 1999-06-14 | 2016-04-26 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical compositions |
US10143698B2 (en) | 1999-06-14 | 2018-12-04 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical compositions |
US10105374B2 (en) | 1999-06-14 | 2018-10-23 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical compositions |
US9532954B2 (en) | 1999-06-14 | 2017-01-03 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical compositions |
US10064878B2 (en) | 1999-06-14 | 2018-09-04 | Cosmo Technologies Ltd. | Controlled release and taste masking oral pharmaceutical compositions |
US20120309959A1 (en) * | 1999-06-14 | 2012-12-06 | Cosmo Technologies Limited | Controlled Release and Taste Masking Oral Pharmaceutical Composition |
US8895064B2 (en) * | 1999-06-14 | 2014-11-25 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US8545811B2 (en) | 2010-03-04 | 2013-10-01 | Cosmo Technologies Ltd. | Solid composition for the oral administration of dyes and diagnostic use thereof |
US9402923B2 (en) | 2010-03-04 | 2016-08-02 | Cosmo Technologies Inc. | Solid composition for the oral administration of dyes and diagnostic use thereof |
US9402922B2 (en) | 2010-03-04 | 2016-08-02 | Cosmo Technologies Inc. | Solid composition for the oral administration of dyes and diagnostic use thereof |
US10265420B2 (en) | 2010-03-04 | 2019-04-23 | Cosmo Technologies Ltd. | Solid composition for the oral administration of dyes and diagnostic use thereof |
US10154964B2 (en) | 2011-09-07 | 2018-12-18 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US10172799B1 (en) | 2011-09-07 | 2019-01-08 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US10307375B2 (en) | 2011-09-07 | 2019-06-04 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US10660858B2 (en) | 2011-09-07 | 2020-05-26 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8293273B2 (en) | Controlled release and taste masking oral pharmaceutical composition | |
US10052286B2 (en) | Controlled release and taste masking oral pharmaceutical composition | |
US10660858B2 (en) | Controlled release and taste masking oral pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |